Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention

BACKGROUND: High-risk percutaneous coronary interventions (PCIs) are associated with a high complication rate, a low procedural success rate and a high restenosis rate, especially in diabetics. We sought to determine whether abciximab (ReoPro(®)) therapy affects long-term clinical outcomes of Korean...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Korean J Intern Med
Egile Nagusiak: Sim, Doo Sun, Jeong, Myung Ho, Kim, Weon, Rhew, Jay Young, Yum, Ju Hyup, Kim, Ju Han, Cho, Jeong Gwan, Ahn, Young Keun, Park, Jong Chun, Ahn, Byoung Hee, Kim, Sang Hyung, Kang, Jung Chaee
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Korean Association of Internal Medicine 2003
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4531627/
https://ncbi.nlm.nih.gov/pubmed/14619381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2003.18.3.129
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak